←
Phillip Kirschberg68,811 posts
Phillip Kirschberg avatar

Phillip Kirschberg

@RushmoreExt23

Smoking/tobacco harm reduction advocate. WNL co-host. ASU Alumni '97 🌹 Not humorless. Personal account. I'd prefer to make the world a better place, and you?

◷ Joined April 2011▧ 7,515 Photos and videos
Phillip Kirschberg avatar
Phillip Kirschberg@RushmoreExt23·Oct 15

Tremendous progress has been made, and you love to see it.

Post attachment

Skip is the first representative of the general public who doesn't actually represent mainstream tobacco control. The four previous holders of the position: - Scout (no first name), an anti-tobacco LGBT activist. - Pebbles Fagan, an anti-tobacco professor engaged in tobacco research (as members of the general public do). - Sonia Duffy, an anti-tobacco nursing professor. - Patricia Nez Henderson, an anti-tobacco Native American activist who wants to "decolonize tobacco" and feels unsafe being in the same room as the tobacco industry.

Phillip Kirschberg avatar
Phillip Kirschberg@RushmoreExt23·1h

“Americans are making choices not only about what they consume, but how. Public health should be able to make those distinctions too.” Changing Habits Demand a More Precise Conversation About Harm, by @RzbkRedMosquito. dcjournal.com/changing-habit…

Clive Bates avatar
⟳ Phillip Kirschberg retweeted
Clive Bates@Clive_Bates·Nov 15

Just on the basis of the fields I know something about (climate, energy, environment, public health), the science that scientists want to save is rarely the science that challenges their priors or punctures a bubble of groupthink. Calls to elevate or protect science are rarely about replication, data sleuthing, or openness - more often a cry for reinforcements to silence contrarian views. “Science” as practiced is pretty poor as true scientific inquiry. Way too much is pointless, flawed, or misrepresented. The profession seems to be unusually attractive to bullies and narcissists - or maybe the pettiness of academic competition selects for those traits. @ArielleSelya

To be honest, I’ve always found partisan calls for “save the science” and “science is back” cringey, but I had trouble articulating it until I read this post. Liz hits the nail on the head with how some of it (sounds? is?) elitist and self-serving for the scientists instead of the general public. But I think that’s only part of it and I will go further. Many pro-science rallying cries just seem to be asking for more science funding without acknowledging the deep problems in science and a plan to address them. People who feel that “the science” has harmed them or is opposing their needs (and this is legitimately happening) are not going to be supportive of more taxpayer dollars perpetuating this. No, we can’t always know which science will lead to discoveries that will improve quality of life, but in my field alone there is a massive amount of money being spent on research that is unproductive, or worse, opposing and gatekeeping progress. And I don’t believe my field is unique. More money is not going to help when the whole system is broken and full of perverse incentives. fromthescienceclass.substack…

Stefan Kertesz, MD, MSc avatar
⟳ Phillip Kirschberg retweeted
Stefan Kertesz, MD, MSc@StefanKertesz·14h

The clinical evaluations that teaching docs fill out on med students and residents have poor validity and almost no predictive value. Why fill them out at all? It is, my cohost suggests, "the tail wagging the dog" We work in a system that wants to rank people, even though it doesn't want to invest seriously in high-quality evaluation. Teaching doctors work in a system where blue-ribbon commissions create impressive "clinical milestones" for us to box-check in a few minutes between emails, after we've been nagged enough to do so. Ranking systems, even fallacious ones, allow residency programs and fellowships to say "we took the best of the best!" But the behemoth of "ranking, no matter how invalid" is not the best use of our medical educational talent. Learn more at "On Becoming a Healer" pod.link/healer/episode/ZjI3…

4:16
Tamar Haspel avatar
⟳ Phillip Kirschberg retweeted
Tamar Haspel@TamarHaspel·Nov 17

How Crap Science Drives Public Opinion A story in 3 acts. Act 1: Enviro group publishes crap study on link between nitrate levels in drinking water & cancer in peer-reviewed journal. (It's not hard!) sciencedirect.com/science/ar…

Phillip Kirschberg avatar
Phillip Kirschberg@RushmoreExt23·22h

NB: “Not only is there a continuum of risk (among different tobacco/nicotine products), but also a continuum of dependence. For example, based on quit rates of different products, it appears much easier to quit smokeless tobacco than cigarettes, and still easier to quit NRT products. This is because smoking a cigarette yields a large and rapid “spike” in nicotine absorption, whereas using most noncombusted products gives a more gradual, flattened nicotine delivery that doesn’t rise to the same levels.” Click below for additional information on the continuum of dependence: academic.oup.com/ntr/article…

Post attachment

Fantastic article by @ArielleSelya via @ACSHorg. Get into it. acsh.org/news/2026/11/17/vap…

Gregory Conley avatar
⟳ Phillip Kirschberg retweeted
Gregory Conley@GregTHR·23 Mar 2022

A positive moment from #SRNT2022: @RU_CTS's @CrisDelnevo points out tobacco control's tendency to get distracted by new, bright shiny objects. Remember dissolvable tobacco?

2:10
Joe Gitchell avatar
⟳ Phillip Kirschberg retweeted
Joe Gitchell@jgitchell·Nov 17

🚨🚨WARNING🚨🚨 Please only read if you appreciate the chance to update your priors.

My new article for @ACSHorg for Lung Cancer Awareness Month. What do we know (and don't know) about e-cigarettes and lung cancer? And what's the role of misinformation about vaping?

Jonathan Foulds PhD avatar
⟳ Phillip Kirschberg retweeted
Jonathan Foulds PhD@JonathanFoulds·Nov 17

Lars Ramstrom (1931-2026), a giant in tobacco research, passed away earlier this month at the age of 95. Originally trained in mathematics and natural sciences he first became involved in tobacco research in the 1970’s, publishing articles on smoking and lung cancer, encouraging the medical profession to help patients who smoke to quit, and writing on the harms of passive smoking. He was Secretary General of the Fourth World Conference on Smoking and Health in Stockholm in 1979, and in 1988 he was the recipient of a WHO Award for achievements in Tobacco Control. One of his earliest papers (1990) on Swedish snus (moist oral smokeless tobacco) acknowledged that it has a lower cancer risk than smoking but warned that in young people it could be the first step on towards taking up cigarettes (1). However, he continued to monitor the patterns of cigarette smoking and snus use among men and women in Sweden along with the patterns of smoking-related diseases and became more and more convinced by the emerging data that among men in particular, use of snus was directly replacing cigarette smoking and lowering smoking-caused mortality. In a letter published in The Lancet in 1992, co-authored with Karl Fagerstom and Torgny Svensson, (in the context of a ban on the sale of oral tobacco products in the European Union), Ramstrom and his colleagues outlined the basic guiding principle of tobacco harm reduction: “Tobacco control efforts should be based on a comprehensive combination of various strategies…..to obtain the best reduction of tobacco-related morbidity and mortality and, thus, to promote health.” (2) As they recommended, Sweden obtained an exemption from the smokeless tobacco ban when it joined the EU in 1995. Lars became a member of SRNT in 1998 and from the beginning of the 21st century he collaborated with a host of Swedish and international colleagues in publishing a series of papers demonstrating that in Sweden the availability of snus appears to have contributed to unusually low rates of smoking among men, with a corresponding reduction in rates of lung cancer and myocardial infarction (3,4,5). Lars Ramstrom was the winner of the 2018 Michael Russell Award in recognition of his contribution to tobacco harm reduction through science and scholarship. One of his nomination letters stated: “ It takes an extraordinary openness to facts and a lot of personal courage for a Swedish scientist to change their mind and take a harm reduction approach in tobacco at the age of 65, after 25 years in tobacco control. It takes heroism and true dedication to health to actively continue to defend that position in a person at the age of 86 with comprehensive and always compelling analysis of the latest data." The comment about personal courage reflects the reality that many colleagues in tobacco control both in Sweden and abroad were critical of his evidence-based focus on improving health. Although Lars Ramstrom’s work was not funded by any tobacco companies, he may have taken some satisfaction when in 2015 General Snus was the first tobacco product to be authorized for marketing in the United States via a pathway requiring strong evidence that its sale on the US market is “appropriate for the protection of public health”. In 2019, after many years of thorough review of the evidence by FDA, General Snus was also the first product to obtain a “Modified Risk” designation from FDA, allowing the manufacturer to state on its US tins that: “Using General Snus instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” (6) In 2025 daily snus prevalence in Sweden was 15% and daily cigarette smoking was 3.7% (7), the lowest daily smoking rate in Europe. Sweden also continues to have the lowest rates of smoking-related mortality in Europe including unusually low rates of oral and lung cancer. Lars Ramstrom published his last journal article on snus and public health in 2024 when he was 93 (8). His brave and diligent research over decades made a great contribution to our understanding of the potential societal health effects of lower risk nicotine products and the lessons to be learned from the Swedish Experience. He truly was a pioneer. 1. Nordgren P, Ramstrom 1990 pubmed.ncbi.nlm.nih.gov/2224… 2. Fagerstrom KO, Ramstrom LM, Svensson TH 1992. pubmed.ncbi.nlm.nih.gov/1348… 3. Foulds J, Ramstrom L, Burke M, Fagerstrom K 2003. pubmed.ncbi.nlm.nih.gov/1466… 4. Ramstrom LM, Foulds J. 2006. pubmed.ncbi.nlm.nih.gov/1672… 5. Ramstrom L, Borland R, Wilkmans T 2016. pubmed.ncbi.nlm.nih.gov/2783… 6. FDA 2019. prnewswire.com/news-releases… 7. Swedish Council for Information on Alcohol and Other Drugs (CAN) can.se/app/uploads/2026/03/c… Ramstrom LM. 2024 pubmed.ncbi.nlm.nih.gov/3932…